Staphylococcus aureus

Kirkman(R) Launches Certified Prenatal Supplement

Retrieved on:

Mittwoch, April 24, 2024

Portland, Oregon--(Newsfile Corp. - April 24, 2024) - Kirkman®, a premier global leader in the dietary supplement industry, has introduced the first certified prenatal supplement that follows FIGO's (International Federation of Gynecology and Obstetrics) position and recommendation after their October 2023 FIGO Statement.

Key Points:

Portland, Oregon--(Newsfile Corp. - April 24, 2024) - Kirkman®, a premier global leader in the dietary supplement industry, has introduced the first certified prenatal supplement that follows FIGO's (International Federation of Gynecology and Obstetrics) position and recommendation after their October 2023 FIGO Statement.
In addition to being recognized as the Top Supplement Manufacturing Company in 2023 by the Food Business Review, Kirkman has developed the P2i by Kirkman prenatal supplement with the support and guidance of OBGYN's, becoming the only Purity-Certified prenatal product in the market.
"We are very excited about launching this prenatal supplement to benefit the human development journey.
To learn more about P2i by Kirkman and their certified prenatal supplement, visit their website: https://www.kirkmangroup.com/p2i-prenatal.html

Chemical pollutants can change your skin bacteria and increase your eczema risk − new research explores how

Retrieved on:

Dienstag, April 23, 2024

Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.

Key Points:

Also known as atopic dermatitis, this chronic skin disease affects about 1 in 5 children in the industrialized world.
Some studies have found rates of eczema in developing nations to be over thirtyfold lower compared with industrialized nations.
Scientists know that factors such as diets rich in processed foods as well as exposure to specific detergents and chemicals increase the risk of developing eczema.
Living near factories, major roadways or wildfires increase the risk of developing eczema.

There’s something in the air

Then we looked at databases from the U.S. Environmental Protection Agency to see which chemicals were most common in those areas.
Diisocyanates were first manufactured in the U.S. around 1970 for the production of spandex, nonlatex foam, paint and polyurethane.
The manufacture of xylene also increased around that time, alongside an increase in the production of polyester and other materials.

After 1975, when all new cars became outfitted with a new technology that converted exhaust gas to less toxic chemicals, isocyanate and xylene both became components of automobile exhaust.
How directly exposing mice to these toxins compares to the typical levels of exposure in people is still unclear.

Skin microbiome and pollution

Every person is coated with millions of microorganisms that live on the skin, collectively referred to as the skin microbiome.
You’ve probably seen moisturizers and other skin products containing ceramides, a group of lipids that play an important role in protecting the skin.

To see which toxins could prevent production of the beneficial lipids that prevent eczema, my team and I used skin bacteria as canaries in the coal mine.
Lysine helps protect the bacteria from the harms of the toxins but doesn’t provide the health benefits of ceramides.
Bacteria that help keep skin healthy could live on any fabric, but, just as with air pollution, the amount of beneficial lipids they made dropped to less than half the levels made when grown on fabrics like cotton.

Addressing pollution’s effects on skin

Detectors capable of sensing low levels of isocyanate or xylene could help track pollutants and predict eczema flare-ups across a community.
Better detectors can also help researchers identify air filtration systems that can scrub these chemicals from the environment.
In the meantime, improving your microbial balance may require avoiding products that limit the growth of healthy skin bacteria.
I believe that it may one day allow us to get back to a time when these diseases were uncommon.

Ian Myles receives funding from the Department of Intramural Research at the National Institute of Allergy and Infectious Diseases. He is the author of, and receives royalties for, the book GATTACA Has Fallen: How population genetics failed the populace. Although he is the co-discoverer of Roseomonas mucosa RSM2015 for eczema, he has donated the patent to the public and has no current conflict of interest for its sales.

Infections after surgery are more likely due to bacteria already on your skin than from microbes in the hospital − new research

Retrieved on:

Mittwoch, April 10, 2024

Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.

Key Points:

Genetic data from the bacteria causing these infections – think CSI for E. coli – tells another story: Most health care-associated infections are caused by previously harmless bacteria that patients already had on their bodies before they even entered the hospital.
We show that many surgical site infections after spinal surgery are caused by microbes that are already on the patient’s skin.

Surgical infections are a persistent problem

Among the different types of heath care-associated infections, surgical site infections stand out as particularly problematic.
A 2013 study found that surgical site infections contribute the most to the annual costs of hospital-acquired infections, totaling over 33% of the US$9.8 billion spent annually.

Still, surgical site infections occur following about 1 in 30 procedures, typically with no explanation.
While rates of many other medical complications have shown steady improvement over time, data from the Agency for Healthcare Research and Quality and the Centers for Disease Control and Prevention show that the problem of surgical site infection is not getting better.

BYOB (Bring your own bacteria)

Prior studies on surgical site infection have been limited to a single species of bacteria and used older genetic analysis methods.
But new technologies have opened the door to studying all types of bacteria and testing their antibiotic resistance genes simultaneously.
Over a one-year period, we sampled the bacteria living in the nose, skin and stool of over 200 patients before surgery.

In fact, 86% of the bacteria causing infections after spine surgery were genetically matched to bacteria a patient carried before surgery.
That number is remarkably close to estimates from earlier studies using older genetic techniques focused on Staphylococcus aureus.
They likely acquired these antibiotic-resistant microbes through prior antibiotic exposure, consumer products or routine community contact.

Preventing surgical infections

At face value, our results may seem intuitive – surgical wound infections come from bacteria that hang out around that part of the body.
If the most likely source of surgical infection – the patient’s microbiome – is known in advance, this presents medical teams with an opportunity to protect against it prior to a scheduled procedure.
The fact that most infections don’t actually start with sources in the hospital is probably a testament to the efficacy of these protocols.

Dustin Long receives funding from the National Institutes of Health. Dr Bryson-Cahn receives funding from the Gordon and Berry Moore Foundation and is the co-medical director for Alaska Airlines.

Recce Pharmaceuticals Granted New Patent in Israel for RECCE® Anti-Infectives

Retrieved on:

Donnerstag, April 4, 2024

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.

Key Points:

SYDNEY, Australia, April 04, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced that the State of Israel Patent Office has formally granted Recce a new family four patent (patent number: 295116), “Process for Preparation of Biologically Active Copolymer Comprising an Acrolein Derivative and a Polyalkylene Glycol Oligomer,” with expiry in 2041.
“We are thrilled to have received this newly granted patent in Israel,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
Israel’s pharmaceuticals and biotechnology market has a reputation for high R&D spending and an impressive international reach, with world-class export numbers and a growing market value.
Other examples include influenza A, Ross River virus, and coronaviruses, including those responsible for severe acute respiratory syndrome and SARS-CoV-2 (COVID-19).

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Retrieved on:

Donnerstag, April 4, 2024

David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.

Key Points:

David Veitch, Chief Executive Officer of Basilea, said: “We are excited with the US approval of ZEVTERA.
The positive decision by the FDA is a key milestone towards bringing ZEVTERA to patients in the US.
This approval is a landmark for ceftobiprole and reflects its broad clinical utility.
Through this partnership, Basilea has been awarded approximately USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work.

Evaxion and Undisclosed Collaborator Announce Encouraging Results for EVX-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Retrieved on:

Dienstag, April 2, 2024

S. aureus, Risk, Patient, Tissue, Staphylococcus aureus, Infection, CDC, Staphylococcus, Animal, Antigen, Vaccine

In the animal studies, the EVX-B1 antigens significantly reduced disease burden.

Key Points:

In the animal studies, the EVX-B1 antigens significantly reduced disease burden.
Birgitte Rønø, Chief Scientific Officer at Evaxion, expresses enthusiasm: “We are very thrilled about the encouraging data and believe that our EVX-B1 vaccine antigens hold the potential for efficacy in human trials – a milestone that previous vaccine attempts have failed to achieve.”
There is no S. aureus vaccine available for human use.
Also, the presence of antibiotic-resistant S. aureus is limiting available treatment options.
The Centers for Disease Control and Prevention (CDC) has reported 120,000 bloodstream infections associated with S. aureus in the US annually.

Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension

Retrieved on:

Montag, März 25, 2024

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for ciprofloxacin and dexamethasone otic suspension.

Key Points:

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced it has received Abbreviated New Drug Application (“ANDA”) approval from the U.S. Food and Drug Administration (“FDA”) for ciprofloxacin and dexamethasone otic suspension.
“This approval represents the addition of another complex, high value medicine,” said Andy Boyer, Executive Vice President, Chief Commercial Officer - Generics.
“It reflects the ongoing shift of our leading affordable medicines portfolio towards complex products and the continued successful diversification of our business.”
The most common adverse reactions reported with ciprofloxacin and dexamethasone otic suspension were ear pain (2.3%), ear discomfort (3%), and ear pruritus (1.5%).
For full prescribing information, see package insert located here .

Asep Medical Confirms the Use of AI - Enables Improved Treatments for Common Biofilm Infections and Rapid Sepsis Diagnostics

Retrieved on:

Donnerstag, März 14, 2024

These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.

Key Points:

These markets include oral health (dental) care4, wounds5 and chronic rhinosinusitis6, all addressed by Asep peptides that show excellent activity in model infections.
AI was also used to simplify the extreme complexity7 of sepsis, which has limited treatments to date.
While others are trying to figure out how AI can be best used, we are already using it with amazing success in diagnostics and therapeutics.
Asep Inc. is dedicated to leveraging AI's power to improve human health," said Dr. Evan Haney, Chief Scientific Officer of Asep.

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Retrieved on:

Mittwoch, März 6, 2024

Conference call, Pseudomonas aeruginosa, DFO, Staphylococcus, Infection, Biotechnology, Cystic fibrosis, EST, NESS, Sale, Conference, Staphylococcus aureus, Amputation, Cystic Fibrosis Foundation, Phage therapy, Patient, APT, OrbiMed, Pharmaceutical industry

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”). Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity of BiomX and APT. The Acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement. Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive purchase agreement for the sale of shares of newly created non-voting convertible preferred stock (“Series X Preferred Stock”) and warrants to purchase shares of BiomX common stock in a private placement to certain institutional accredited investors led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital. The private placement is expected to result in gross proceeds to BiomX of $50 million before deducting placement agent and other offering expenses. The proceeds from the private placement are expected to provide funding through the results from a planned Phase 2b trial that will evaluate BiomX’s lead product candidate, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (P. aeruginosa) in CF patients expected in the third quarter of 2025 and Phase 2 results from APT’s clinical-stage product candidate, now named BX211, for the treatment of Staphylococcus aureus (S. aureus) infections in DFO patients expected in the first quarter of 2025. The private placement is expected to close substantially concurrently with, and subject to the closing of, the Acquisition.

Key Points:

Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity of BiomX and APT.
The Acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement.
The private placement is expected to result in gross proceeds to BiomX of $50 million before deducting placement agent and other offering expenses.
The private placement is expected to close substantially concurrently with, and subject to the closing of, the Acquisition.

LG'S HOME LIFESTYLE SOLUTIONS PRESENT COMFORT AND CONVENIENCE AT KBIS 2024

Retrieved on:

Freitag, Februar 23, 2024

SEOUL, South Korea, Feb. 23, 2024 /PRNewswire/ -- LG Electronics (LG) is unveiling a range of home lifestyle solutions at the 2024 Kitchen & Bath Industry Show (KBIS) in Las Vegas, USA, from February 27-29. The company's latest innovations, including the bath solution, PuriCare™ HydroTower and system ironing, use sophisticated technologies and user-friendly design to elevate and enrich daily living.

Key Points:

LG is expanding enhanced customer experience to the bathroom, one of the main living spaces in the home, by presenting a bath solution that provides convenience and comfort.
For greater comfort in the shower, LG's Smart Bath and Shower Purifier leverages thermostatics to maintain the selected water temperature.
Making its international debut at KBIS 2024, the HydroTower was successfully launched in South Korea last year, where it surpassed 10,000 units sold in only 50 days.
LG's new home solutions will be on display at the company's exhibition booth (West Hall #2343, Las Vegas Convention Center) during KBIS 2024 in Las Vegas, Nevada.